MYCIT

Pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteins; personalised patient-specific medicinal products, in particular based on nucleic acids and/or proteins, namely, pharmaceutical preparations for treatment of cancer diseases, autoimmune diseases, and infectious diseases

Scientific apparatuses and instruments, namely, next generation sequencers for laboratory research use; software algorithms, namely, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients

High-throughput analytical instruments, in particular instruments for next-generation sequencing (NGS) for medical issues, as well as for gene expression profiling and for the detection of epigenetic changes, namely, high throughput genome and exome gene sequencers for medical use

Medical research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and treatment by means of molecular-biological, genetic, biotechnological and/or bioinformatic methods, in particular by means of next-generation sequencing; Scientific laboratory services and scientific research services featuring diagnostics of tumour markers for personalised treatment

Medical, veterinary-medical and pharmaceutical advisory services, in particular in the selection of suitable treatments for cancer diseases of all kinds; Medical services, namely, performance of analyses and treatments as part of personalised cancer immunotherapy; Medical services for the treatment of cancer, namely, provision of treatments based on nucleic acids and/or checkpoint inhibitors